Share on LinkedInShare on LinkedIn

ARTICLE · 18 OCTOBER 2015

How does the recent High Court patent case affect the research and innovation pathway for biologicals?

We discuss D'Arcy v Myriad Genetics Inc. [2015] HCA 35 7 October 2015.

AustraliaIntellectual Property

D'Arcy v Myriad Genetics Inc. [2015] HCA 35 7 October 2015

The recent High Court Case of D'Arcy v Myriad Genetics Inc. & Anor [2015] HCA 35 highlights the debate over balancing:

  1. the rights of inventors and creators to commercialise and profit from their inventions; and
  2. the interests and needs of the wider society to be able to access biological developments for research and the improvement of public health and welfare.

Those seeking the protection of intellectual property rights argue that the protection of exclusive rights to the intellectual property enables investment which is necessary for the expensive process of taking research to clinical trials, commercialisation and the market.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from